tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Granuloma Annulare D016460 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Lauzurica R et al. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. 2007 Transplant. Proc. pmid:17889127
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Pérez-Flores I et al. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. 2009 Jul-Aug Transplant. Proc. pmid:19715845
Cherala G et al. Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation. 2011 Transplant. Proc. pmid:22172831
Spinelli GA et al. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. 2011 Transplant. Proc. pmid:22172836
Urbizu JM et al. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience. 2002 Transplant. Proc. pmid:11959197
Stringa P et al. Pretreatment Combination Reduces Remote Organ Damage Secondary to Intestinal Reperfusion Injury in Mice: Follow-up Study. Transplant. Proc. pmid:26915870
Soda M et al. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Transplant. Proc. pmid:28736028
Mac Guad R et al. Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:26915847
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Ringe B et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. 1998 Transplant. Proc. pmid:9636573
Shimizu T et al. Risk factors of acute tacrolimus nephrotoxicity in renal allografts. 2000 Transplant. Proc. pmid:11119998
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Rudich SM et al. Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. 1998 Transplant. Proc. pmid:9636574
Chueh SC et al. Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report. 2000 Transplant. Proc. pmid:11120003
Ueno T et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. 2006 Jul-Aug Transplant. Proc. pmid:16908274
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Bora F et al. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients. 2012 Transplant. Proc. pmid:23195020
Crespo-Leiro MG Calcineurin inhibitors in heart transplantation. 2005 Transplant. Proc. pmid:16386614
Rucay P et al. FK 506 as treatment of late acute rejection in liver transplant patients. 1995 Transplant. Proc. pmid:7533354
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
Oppenheimer F Steroid withdrawal in renal transplant recipients. 2000 Transplant. Proc. pmid:10686314
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Jain A et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. 2005 Transplant. Proc. pmid:15848671
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Niederstadt C et al. Effect of FK506 on magnesium homeostasis after renal transplantation. 1997 Transplant. Proc. pmid:9365709
Chen J et al. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. 2008 Transplant. Proc. pmid:18589119
Jonas S et al. Cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up. 2002 Transplant. Proc. pmid:12176459
Chen JW et al. Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176460
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Fukuzaki T et al. Induction of unresponsiveness to islet allografts with donor spleen cell inoculation followed by a single injection of FK 506. 1995 Transplant. Proc. pmid:7533407
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Mortensen DM et al. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation. 2006 Transplant. Proc. pmid:17098028
Loucaidou M et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. 2005 Transplant. Proc. pmid:15919469
Malyszko J et al. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. 2009 Transplant. Proc. pmid:19857675
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Kitamura M et al. Clinical experience of FK 506 for renal allograft transplantation. 1994 Transplant. Proc. pmid:7520611
Lo CM et al. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. 1998 Transplant. Proc. pmid:9838571
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Reichenspurner H et al. Tacrolimus-based immunosuppressive protocols in lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083062
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Mange KC and Bloom RD Rates of acute rejection by recipient race and type of calcineurin inhibitor with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12493393
Domenech N et al. Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. 2003 Transplant. Proc. pmid:12962873
Boots JM et al. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? 2002 Transplant. Proc. pmid:12493409
Peraira JR et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. 2003 Transplant. Proc. pmid:12962875
Khanna A et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123118
Busuttil RW and Holt CD Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123119
Villanueva ME et al. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. 2008 Transplant. Proc. pmid:18790198
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Wayman MR et al. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. 2002 Transplant. Proc. pmid:12176526
Cho WH et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. 2008 Transplant. Proc. pmid:18790201
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Okamoto M et al. Tacrolimus-based immunosuppression in renal transplantation: 78 experiences in a single Japanese center. 2002 Transplant. Proc. pmid:12176527
Kim JD et al. Single-Center Experience of ABO-Incompatible Living-Donor Liver Transplantation With a New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score-Matching Analysis. 2016 Transplant. Proc. pmid:27320573
Weinbroum AA et al. Lack of cumulative effect of tacrolimus and low flow on a rat isolated liver. 2001 Transplant. Proc. pmid:11543812
Jacobs TW et al. The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. 1991 Transplant. Proc. pmid:1721403
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ohdan H et al. Prolongation of hamster-to-rat liver xenograft survival by donor bone marrow augmentation. 1997 Feb-Mar Transplant. Proc. pmid:9123589
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Uber PA et al. Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: surrogate evidence for cardiac adaptation. 2002 Transplant. Proc. pmid:12176598
van den Berg AP et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. 2001 Feb-Mar Transplant. Proc. pmid:11267197
Wu M et al. Cyclosporine and tacrolimus alter renin-angiotesin system in mouse medullary-thick ascending limb cultured cells. 2001 Feb-Mar Transplant. Proc. pmid:11267198
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Wada H et al. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. 1991 Transplant. Proc. pmid:1721435
Filler G et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. 2004 Transplant. Proc. pmid:15251324
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Ghio L et al. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. 2004 Transplant. Proc. pmid:15251325
Calne R et al. Observations about FK-506 in primates. 1987 Transplant. Proc. pmid:2445078
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Chen H et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9745497
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Renner FC et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. 2013 Transplant. Proc. pmid:23726630
Walgenbach KJ et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. 1998 Transplant. Proc. pmid:9745501
Laftavi MR et al. The role of antibiotic prophylaxis in the new era of immunosuppression. 2011 Transplant. Proc. pmid:21440753
Jordan ML et al. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267456
Fu Q et al. Risk Factors for Acute Rejection After Deceased Donor Kidney Transplantation in China. 2018 Transplant. Proc. pmid:30316380
Chen H et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9636419
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Li S et al. Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. 1998 Transplant. Proc. pmid:9636431
Pinho-Apezzato ML et al. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. 2010 Transplant. Proc. pmid:20620519
Miki T et al. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. 1998 Transplant. Proc. pmid:9636444
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Suarez Benjumea A et al. Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication. 2016 Transplant. Proc. pmid:27932111
Halim MA et al. De novo Crohn's disease in a renal transplant recipient. 2007 Transplant. Proc. pmid:17524953
Rathi M et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. 2015 Transplant. Proc. pmid:26036543
Henley SE et al. Lipids following pancreas transplantation in recipients receiving FK 506. 1995 Transplant. Proc. pmid:8539809
Pridöhl O et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. 2001 Nov-Dec Transplant. Proc. pmid:11750384